Berger Financial Group Inc Lowers Position in Danaher Corporation $DHR

Key Points

• Berger Financial Group Inc reduced its stake in Danaher Corporation by 77.4%, owning only 1,344 shares after selling 4,612 shares in the second quarter, with holdings valued at $265,000.
• Several institutional investors, including Vanguard Group and Price T Rowe Associates, have increased their positions in Danaher during the first quarter, indicating continued institutional interest in the stock.
• Danaher reported a quarterly EPS of $1.80, beating consensus estimates and projected FY 2025 guidance of $7.700-$7.800 EPS, along with announcing a quarterly dividend of $0.32 per share set to be paid on October 31st.

Berger Financial Group Inc decreased its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 77.4% during the second quarter, according to its most recent filing with the SEC. The firm owned 1,344 shares of the conglomerate's stock after selling 4,612 shares during the period. Berger Financial Group Inc's holdings in Danaher were worth $265,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in DHR. Vanguard Group Inc. lifted its position in Danaher by 0.4% during the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after buying an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Danaher by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after acquiring an additional 612,154 shares during the period. Bank of New York Mellon Corp boosted its stake in Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after acquiring an additional 194,466 shares in the last quarter. Invesco Ltd. boosted its stake in Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after acquiring an additional 1,450,703 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Danaher by 4.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate's stock worth $867,168,000 after purchasing an additional 163,332 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Activity

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 11.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. UBS Group dropped their price target on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Robert W. Baird lifted their price objective on Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Bank of America cut their target price on Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a research note on Monday, September 22nd. Royal Bank Of Canada set a $241.00 price target on Danaher in a research report on Tuesday, September 2nd. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Danaher in a research report on Saturday, September 27th. Seventeen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $245.91.

Danaher Price Performance

NYSE DHR opened at $211.65 on Tuesday. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41. The stock has a 50-day moving average of $200.36 and a 200 day moving average of $197.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The company has a market capitalization of $151.55 billion, a price-to-earnings ratio of 45.03, a PEG ratio of 3.06 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter last year, the firm posted $1.72 EPS. The business's quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio is presently 27.23%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.